Biocryst Pharmaceuticals (BCRX) Invested Capital (2016 - 2026)

Biocryst Pharmaceuticals' Invested Capital history runs 10 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• Quarterly Invested Capital fell 41.4% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.0 million (down 23.98% YoY) and the FY2025 annual result came in at $2.8 million, down 30.46% from the prior year.
• Invested Capital was $2.4 million for Q1 2026 at Biocryst Pharmaceuticals, down from $2.8 million in the prior quarter.
• Across five years, Invested Capital topped out at $4.4 million in Q4 2023 and bottomed at $2.4 million in Q1 2026.
• A 5-year average of $3.5 million and a median of $3.8 million in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2023 — Invested Capital soared 68.63% — and 2026, when it sank 41.4%.
• Biocryst Pharmaceuticals' Invested Capital stood at $2.6 million in 2022, then jumped by 68.63% to $4.4 million in 2023, then fell by 10.73% to $4.0 million in 2024, then slumped by 30.46% to $2.8 million in 2025, then fell by 12.53% to $2.4 million in 2026.
• Business Quant data shows BCRX's Invested Capital at $2.4 million in Q1 2026, $2.8 million in Q4 2025, and $3.2 million in Q3 2025.